Content about Retinoids

March 29, 2013

Dr. Reddy's has launched a drug for treating acne, the company said Friday.

HYDERABAD, India — Dr. Reddy's has launched a drug for treating acne, the company said Friday.

The Indian generic drug maker announced the launch of Zenatane (isotretinoin) capsules in the 20-mg and 40-mg strengths. The drug is a therapeutically equivalent generic version of Roche's Accutane. The Food and Drug Administration also approved the drug in the 10-mg strength.

Various versions of the drug had sales of about $309 million during the 12-month period that ended in January, according to IMS Health.

February 21, 2013

Valeant buys rights to Eisai's Targretin

Valeant Pharmaceuticals has bought rights to a drug used to treat skin cancer from Eisai, the companies said Thursday.

WOODCLIFF LAKE, N.J. — Valeant Pharmaceuticals has bought rights to a drug used to treat skin cancer from Eisai, the companies said Thursday.

Valeant has bought the rights to Targretin (bexarotene) capsules and gel from Eisai for $65 million upfront, plus additional payments based on certain milestones. Under the deal, Eisai has transferred its regulatory approval application to Valeant, which will assume responsibilities for all regulatory obligations associated with the product in the United States. Eisai will retain rights to the drug outside the United States.

November 26, 2012

Ranbaxy launches branded acne drug

Ranbaxy Labs has launched a new treatment for acne under a licensing agreement with a Canadian drug maker.

PRINCETON, N.J. — Ranbaxy Labs has launched a new treatment for acne under a licensing agreement with a Canadian drug maker.

Ranbaxy announced Monday the launch of Absorbica (isotretinoin) capsules for treating severe recalcitrant nodular acne in patients ages 12 years and older. The drug was launched under a license from Mississauga, Ontario-based Cipher Pharmaceuticals.

Normally, oral isotretinoin must be taken with a high-fat meal due to its chemical properties, but Absorbica is designed to be taken without food.

July 30, 2012

Watson seeks approval for acne, bronchospasm drugs

Generic drug maker Watson Pharmaceuticals is challenging the patent protection on a drug for acne and a drug for bronchospasm, the company said Monday.

PARSIPPANY, N.J. — Generic drug maker Watson Pharmaceuticals is challenging the patent protection on a drug for acne and a drug for bronchospasm, the company said Monday.

June 21, 2012

New Drugs — Chain Pharmacy, 6/25/12

The Food and Drug Administration has approved a branded acne drug made by Ranbaxy Labs, the drug maker said. Ranbaxy announced the FDA approval of Absorica (isotretinoin), a drug for treating severe recalcitrant nodular acne.

The Food and Drug Administration has approved a branded acne drug made by Ranbaxy Labs, the drug maker said. Ranbaxy announced the FDA approval of Absorica (isotretinoin), a drug for treating severe recalcitrant nodular acne. The company expects to launch it in the United States in fourth quarter 2012 under an agreement with Canada-based Cipher Pharmaceuticals. 

May 30, 2012

FDA approves Ranbaxy acne drug

The Food and Drug Administration has approved a branded acne drug made by Ranbaxy Labs, the drug maker said.

PRINCETON, N.J. — The Food and Drug Administration has approved a branded acne drug made by Ranbaxy Labs, the drug maker said.

Ranbaxy announced the FDA approval of Absorica (isotretinoin), a drug for treating severe recalcitrant nodular acne. The company expects to launch Absorica in the United States in fourth quarter 2012 under an agreement with Canada-based Cipher Pharmaceuticals.

May 23, 2012

FDA approves Stiefel acne treatment

The Food and Drug Administration has approved a new treatment for acne made by a GlaxoSmithKline subsidiary.

NEW YORK — The Food and Drug Administration has approved a new treatment for acne made by a GlaxoSmithKline subsidiary.

Stiefel announced the approval of Fabior (tazarotene) foam in the 0.1% strength, calling it the only retinoid in a topical foam for treating acne in patients ages 12 years and older.

"Stiefel is dedicated to meeting th needs of patients and dermatologists, and we believe Fabior foam will be an important treatment option for people with moderate-to-severe acne," Stiefel VP North America dermatology Jean-Christophe May said.

February 29, 2012

Murad develops new Time Release retinol concentrate for deep wrinkles

Murad, whose products are sold at salons, spas, Sephora and Ulta, is bringing to market in March its new Time Release retinol concentrate for deep wrinkles, featuring new technology that is designed to control the release of retinol over time for maximum performance while improving the stability and efficacy of the product.

EL SEGUNDO, Calif. — Murad, whose products are sold at salons, spas, Sephora and Ulta, is bringing to market in March its new Time Release retinol concentrate for deep wrinkles, featuring new technology that is designed to control the release of retinol over time for maximum performance while improving the stability and efficacy of the product.

December 13, 2011

FTC approves Valeant's acquisitions of Dermik, Ortho Dermatologics

The Federal Trade Commission has voted to approve Valeant's acquisitions of Dermik, a unit of French drug maker Sanofi that makes drugs for skin conditions, and Ortho Dermatologics, a division of Johnson & Johnson that also makes skin drugs.

MISSISSAUGA, Ontario — The Federal Trade Commission has voted to approve Valeant's acquisitions of Dermik, a unit of French drug maker Sanofi that makes drugs for skin conditions, and Ortho Dermatologics, a division of Johnson & Johnson that also makes skin drugs.

October 11, 2011

FDA accepts application for Banner Pharmacaps' generic cancer drug

The Food and Drug Administration has accepted the first regulatory approval application for a generic version of a cancer drug made by Eisai.

HIGH POINT, N.C. — The Food and Drug Administration has accepted the first regulatory approval application for a generic version of a cancer drug made by Eisai.

Banner Pharmacaps announced Tuesday that it had filed for regulatory approval of generic bexarotene gelatin capsules in the 75-mg strength, a generic version of Eisai's Targretin, used to treat cutaneous T-cell lymphoma, or CTCL skin cancer. Under the Hatch-Waxman Act of 1984, once the drug is approved, Banner will be the exclusive supplier of a generic version of Targretin for 180 days.

August 4, 2011

Stiefel seeks FDA approval for tazarotene foam

GlaxoSmithKline company Stiefel announced it is seeking approval for a facial acne treatment in patients ages 12 years and older.

RESEARCH TRIANGLE PARK, N.C. — GlaxoSmithKline company Stiefel announced it is seeking approval for a facial acne treatment in patients ages 12 years and older.

Stiefel said it has submitted a new drug application to the Food and Drug Administration for tazarotene foam. Tazarotene foam is subject to evaluation and approval by the regulatory authorities before it can be made available to physicians for prescribing to their appropriate patients, Stiefel said.

July 5, 2011

Brushing on innovation

L’Oréal Paris has combined its cosmetics and skin care expertise into one innovative formula with Visible Lift Smooth Absolute instant age-reversing foundation. 

NEW YORK — L’Oréal Paris has combined its cosmetics and skin care expertise into one innovative formula with Visible Lift Smooth Absolute instant age-reversing foundation. 

The SPF 17 formula is infused with an anti-aging complex, hydra-collagen, which also contains Pro-Retinol A, elastic, collagen and vitamin E. The prestige-inspired, click-through brush sweeps the formula evenly onto skin, providing controllable coverage and a weightless finish. 

July 5, 2010

Fougera's generic Differin gets green light from FDA

The Food and Drug Administration has approved a topical drug for acne made by E....

January 29, 2008

Woodridge introduces 40 carrots skin care

Woodridge Labs has announced the launch of the 40 carrots skin care line that combines...